Alice S. Carter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alice S. Carter has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
Denise O Garrett
Vaccine Epidemiology, Sabin Vaccine Institute , Washington, DC
2 shared publications- Jessica Couvillion Seidman
Sabin Vaccine Institute, Washington, DC, USA
2 shared publications Stephen P Luby
Division of Infectious Diseases and Geographic Medicine, Stanford University , Stanford, California
2 shared publicationsAbhiyan Gautam
National Immunization Program, Department of Health Services, Ministry of Health and Population, Kathmandu, Nepal
1 shared publication- Andrew Duncan Steele
Enterics, Diagnostics, Genomics & Epidemiology, Gates Foundation, Seattle, WA 98109, USA
1 shared publication Aneeta Hotwani
Department of Pediatrics and Child Health, Aga Khan University Hospital, Karachi, Pakistan
1 shared publication
Latest Publications
- Open Access
- 28 September 2026
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 11, 759
A phase IV parallel-group, open-label, randomized non-inferiority trial evaluating immunogenicity of extended dosing intervals for Euvichol-S oral cholera vaccine in Nairobi, Kenya: study protocol for a randomized non-inferiority trial
Background Global shortages of oral cholera vaccine have led to widespread use of single-dose vaccination. Although this approach increases immediate population coverage, protection may be less durable and effectiveness is lower in young children. Evidence remains limited on whether extending the interval before the second dose of Euvichol-S preserves the immune response achieved with the recommended two-week schedule. Protocol This phase IV, parallel-group, open-label, randomized non-inferiority trial is being conducted in Mukuru, Nairobi, Kenya. A total of 1,071 participants aged ≥1 year are being randomized 1:1:1 to receive a second Euvichol-S dose after two weeks, three months, or twelve months. Randomization is stratified by age group: 1–4 years, 5–14 years, and ≥ 15 years. The respective permitted dose-2 windows are Days 11–17, Days 83–97, and Days 351–379. The primary outcome is the plasma vibriocidal antibody response against Vibrio cholerae O1 Inaba and Ogawa, measured 14 days after the second dose. Each extended schedule will be compared with the two-week schedule within each age group using a geometric mean titre ratio and a non-inferiority margin of 0.90. The primary analysis will use the per-protocol population, with intention-to-treat analyses conducted as sensitivity analyses. Secondary outcomes include seroconversion, persistence of vibriocidal responses, laboratory-confirmed cholera, and safety. A paediatric peripheral blood mononuclear cell sub-cohort is evaluating plasmablast and memory B-cell responses. Discussion The trial will provide evidence on whether longer intervals before the second Euvichol-S dose preserve vaccine-induced immune responses across age groups. Because the primary outcome is immunological, implications for clinical protection and vaccination policy will require cautious interpretation. Trial registration: Pan African Clinical Trials Registry, PACTR202501835187008. Registered 28 January 2025.
- 28 September 2026
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 11, 759
Open AccessA phase IV parallel-group, open-label, randomized non-inferiority trial evaluating immunogenicity of extended dosing intervals for Euvichol-S oral cholera vaccine in Nairobi, Kenya: study protocol for a randomized non-inferiority trial
Background Global shortages of oral cholera vaccine have led to widespread use of single-dose vaccination. Although this approach increases immediate population coverage, protection may be less durable and effectiveness is lower in young children. Evidence remains limited on whether extending the interval before the second dose of Euvichol-S preserves the immune response achieved with the recommended two-week schedule. Protocol This phase IV, parallel-group, open-label, randomized non-inferiority trial is being conducted in Mukuru, Nairobi, Kenya. A total of 1,071 participants aged ≥1 year are being randomized 1:1:1 to receive a second Euvichol-S dose after two weeks, three months, or twelve months. Randomization is stratified by age group: 1–4 years, 5–14 years, and ≥ 15 years. The respective permitted dose-2 windows are Days 11–17, Days 83–97, and Days 351–379. The primary outcome is the plasma vibriocidal antibody response against Vibrio cholerae O1 Inaba and Ogawa, measured 14 days after the second dose. Each extended schedule will be compared with the two-week schedule within each age group using a geometric mean titre ratio and a non-inferiority margin of 0.90. The primary analysis will use the per-protocol population, with intention-to-treat analyses conducted as sensitivity analyses. Secondary outcomes include seroconversion, persistence of vibriocidal responses, laboratory-confirmed cholera, and safety. A paediatric peripheral blood mononuclear cell sub-cohort is evaluating plasmablast and memory B-cell responses. Discussion The trial will provide evidence on whether longer intervals before the second Euvichol-S dose preserve vaccine-induced immune responses across age groups. Because the primary outcome is immunological, implications for clinical protection and vaccination policy will require cautious interpretation. Trial registration: Pan African Clinical Trials Registry, PACTR202501835187008. Registered 28 January 2025.
- Open Access
Rotavirus Vaccines at 20 Years: Success, Challenges, and the Road Ahead
Twenty years after the introduction of rotavirus vaccines, the 15th International Rotavirus Symposium convened researchers, clinicians, immunization program managers, and policymakers to review advances in rotavirus epidemiology, immunology, vaccine development, and implementation. Rotavirus vaccination has contributed to sustained reductions in severe rotavirus hospitalizations and child mortality, yet population-level benefits remain heterogeneous and are constrained by gaps in coverage, supply-related program disruptions, and context-specific vaccine performance. Presenters highlighted evidence from multi-pathogen surveillance confirming that rotavirus remains a leading cause of pediatric diarrhea requiring hospitalization despite widespread vaccine introduction. Accumulating evidence implicates maternally derived antibodies, environmental enteric dysfunction, and early-life microbiome development as contributors to reduced oral vaccine performance in low- and middle-income communities, while recent studies of next-generation vaccine candidates underscore the need for improved correlates of protection and clinically meaningful efficacy endpoints. Collectively, the symposium emphasized that further reductions in rotavirus morbidity and mortality will require strengthening delivery of existing vaccines—including improving coverage, minimizing supply interruptions, and reaching zero-dose and under-immunized children—while sustaining surveillance and investing in integrated enteric disease prevention and next-generation vaccines to optimize protection in high-burden settings.
Open AccessRotavirus Vaccines at 20 Years: Success, Challenges, and the Road Ahead
Twenty years after the introduction of rotavirus vaccines, the 15th International Rotavirus Symposium convened researchers, clinicians, immunization program managers, and policymakers to review advances in rotavirus epidemiology, immunology, vaccine development, and implementation. Rotavirus vaccination has contributed to sustained reductions in severe rotavirus hospitalizations and child mortality, yet population-level benefits remain heterogeneous and are constrained by gaps in coverage, supply-related program disruptions, and context-specific vaccine performance. Presenters highlighted evidence from multi-pathogen surveillance confirming that rotavirus remains a leading cause of pediatric diarrhea requiring hospitalization despite widespread vaccine introduction. Accumulating evidence implicates maternally derived antibodies, environmental enteric dysfunction, and early-life microbiome development as contributors to reduced oral vaccine performance in low- and middle-income communities, while recent studies of next-generation vaccine candidates underscore the need for improved correlates of protection and clinically meaningful efficacy endpoints. Collectively, the symposium emphasized that further reductions in rotavirus morbidity and mortality will require strengthening delivery of existing vaccines—including improving coverage, minimizing supply interruptions, and reaching zero-dose and under-immunized children—while sustaining surveillance and investing in integrated enteric disease prevention and next-generation vaccines to optimize protection in high-burden settings.
- Open Access
- 28 April 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (5)
Estimating Enteric Fever Seroincidence in Bangladesh Using Rapid Serosurveys
Background: Enteric fever, caused by Salmonella Typhi or Paratyphi, is a major public health issue in low- and middle-income countries. Accurate burden estimation is hampered by limited microbiological facilities and low sensitivity of blood-culture tests. Serosurveillance offers a scalable alternative to address these challenges. This study estimated the seroincidence of enteric fever in Bangladesh using cross-sectional rapid serosurveys. Methods: School-based surveys (January–June 2022) were conducted in Chattogram, Dinajpur, Sylhet, Satkhira, and Faridpur, and community-based surveys (July 2019–November 2021) were conducted in Dhaka and Mirzapur. Blood samples (dried blood spots or venous blood) were collected and tested for anti-hemolysin E IgG responses using a kinetic enzyme-linked immunosorbent assay. Seroincidence was estimated using a maximum likelihood approach based on peak antibody titers and decay rates, modeled from blood-culture confirmed enteric fever cases in Bangladesh. Findings: A total of 2969 participants aged 0–22 years were enrolled, with 75.5% aged 5–15 years. Seroincidence rates (per 100 person-years) were highest in Dhaka (33.1; 95% confidence interval [CI], 29.0–37.9), followed by Mirzapur (19.5; 95% CI, 17.4–21.7) and Chattogram (17.1; 95% CI, 15.0–19.4), and the lowest in Faridpur (11.1; 95% CI, 9.6–12.7). The under 5 age group exhibited higher rates in Dhaka (40.3; 95% CI, 32.1–50.7) and Mirzapur (26.1; 95% CI, 21.0–32.4) compared to older age groups. Seroincidence was higher in areas with higher population density. Conclusions: This study highlights a substantial burden of enteric fever infections across Bangladesh. These provide important evidence to guide post-introduction monitoring and optimization of the typhoid conjugate vaccine program in the national immunization schedule.
- 28 April 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (5)
Open AccessEstimating Enteric Fever Seroincidence in Bangladesh Using Rapid Serosurveys
Background: Enteric fever, caused by Salmonella Typhi or Paratyphi, is a major public health issue in low- and middle-income countries. Accurate burden estimation is hampered by limited microbiological facilities and low sensitivity of blood-culture tests. Serosurveillance offers a scalable alternative to address these challenges. This study estimated the seroincidence of enteric fever in Bangladesh using cross-sectional rapid serosurveys. Methods: School-based surveys (January–June 2022) were conducted in Chattogram, Dinajpur, Sylhet, Satkhira, and Faridpur, and community-based surveys (July 2019–November 2021) were conducted in Dhaka and Mirzapur. Blood samples (dried blood spots or venous blood) were collected and tested for anti-hemolysin E IgG responses using a kinetic enzyme-linked immunosorbent assay. Seroincidence was estimated using a maximum likelihood approach based on peak antibody titers and decay rates, modeled from blood-culture confirmed enteric fever cases in Bangladesh. Findings: A total of 2969 participants aged 0–22 years were enrolled, with 75.5% aged 5–15 years. Seroincidence rates (per 100 person-years) were highest in Dhaka (33.1; 95% confidence interval [CI], 29.0–37.9), followed by Mirzapur (19.5; 95% CI, 17.4–21.7) and Chattogram (17.1; 95% CI, 15.0–19.4), and the lowest in Faridpur (11.1; 95% CI, 9.6–12.7). The under 5 age group exhibited higher rates in Dhaka (40.3; 95% CI, 32.1–50.7) and Mirzapur (26.1; 95% CI, 21.0–32.4) compared to older age groups. Seroincidence was higher in areas with higher population density. Conclusions: This study highlights a substantial burden of enteric fever infections across Bangladesh. These provide important evidence to guide post-introduction monitoring and optimization of the typhoid conjugate vaccine program in the national immunization schedule.
- Open Access
- 20 July 2024
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 147, 107187
Longevity of immune response after a single dose of typhoid conjugate vaccine against Salmonella Typhi among children in Hyderabad, Pakistan
- 20 July 2024
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 147, 107187
Open AccessLongevity of immune response after a single dose of typhoid conjugate vaccine against Salmonella Typhi among children in Hyderabad, Pakistan
- Open Access
- 1 November 2020
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 71 (Supplement) , S191-S195
Introducing Typhoid Conjugate Vaccine in South Asia: Lessons From the Surveillance for Enteric Fever in Asia Project
Enteric fever remains a public health concern in communities lacking sanitation infrastructure to separate sewage from drinking water. To bridge the gap until large-scale civil-engineering projects are implemented in high-burden countries, typhoid conjugate vaccine presents a promising disease-prevention technology. A new typhoid conjugate vaccine was prequalified by the World Health Organization in 2017 and is beginning to be introduced in countries around the world. To help inform vaccine introduction, the Surveillance for Enteric Fever in Asia Project (SEAP) conducts prospective enteric fever surveillance in Bangladesh, Nepal, and Pakistan. This supplement presents findings from Phase II of the study (2016–2019) on burden of disease, clinical presentation, the growing spread of drug-resistant strains, and policy and economic ramifications. These findings are delivered to support policymakers in their deliberations on strategies to introduce typhoid conjugate vaccine as a preventive tool against enteric fever.
- 1 November 2020
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 71 (Supplement) , S191-S195
Open AccessIntroducing Typhoid Conjugate Vaccine in South Asia: Lessons From the Surveillance for Enteric Fever in Asia Project
Enteric fever remains a public health concern in communities lacking sanitation infrastructure to separate sewage from drinking water. To bridge the gap until large-scale civil-engineering projects are implemented in high-burden countries, typhoid conjugate vaccine presents a promising disease-prevention technology. A new typhoid conjugate vaccine was prequalified by the World Health Organization in 2017 and is beginning to be introduced in countries around the world. To help inform vaccine introduction, the Surveillance for Enteric Fever in Asia Project (SEAP) conducts prospective enteric fever surveillance in Bangladesh, Nepal, and Pakistan. This supplement presents findings from Phase II of the study (2016–2019) on burden of disease, clinical presentation, the growing spread of drug-resistant strains, and policy and economic ramifications. These findings are delivered to support policymakers in their deliberations on strategies to introduce typhoid conjugate vaccine as a preventive tool against enteric fever.